Latest Non-small cell lung carcinoma Stories
TUCSON, Ariz., Jan. 21, 2015 /PRNewswire/ -- Ventana Medical Systems, Inc.
Company expands lung cancer clinical program for its Precision Cancer MonitoringSM solution to up to 700 patients at three leading cancer centers SAN DIEGO, Jan.
- Results from two large trials individually showed an improvement in the secondary endpoint of overall survival for patients with the most common EGFR mutation (Del19) RIDGEFIELD, Conn., Jan.
The Oncology Institute of Hope and Innovation announces first clinical trial of the year. Downey, CA (PRWEB) January 10, 2015 The Oncology Institute
- Discuss interim results for Study 202 evaluating PEGPH20 with gemcitabine and ABRAXANE® in pancreatic cancer patients - SAN DIEGO, Jan.
Lung cancer cells can spread more easily than other types of cells because the protein ties that tether them together are severed, allowing them to break loose, a team of researchers from the Cancer Research UK Manchester Institute report in a new study.
CYRAMZA is the first treatment approved in the U.S. for use in combination with docetaxel in second-line metastatic non-small cell lung cancer INDIANAPOLIS, Dec.
The FDA has approved the drug Cyramza, to be used in combination with docetexal for the treatment of non-small-cell lung cancer (NSCLC).
SAN DIEGO, Dec.
Frontier Pharma - NSCLC - Identifying and Commercializing First-in-Class Innovation in Non-Small-Cell Lung Carcinoma provides information on pricing, market analysis, shares, forecast, and company
- Monstrous in size or character; huge; prodigious; monstrously perverse, savage, cruel, etc.